News | Radiopharmaceuticals and Tracers | March 09, 2017

First Diagnostic Radiotracer for Early Alzheimer's Diagnosis Approved in Canada

NeuraCeq (florbetaben F-18 injection) PET tracer has already received approval in the U.S., as well as several countries in Europe and Asia

X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg

March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health Canada has issued a Notice of Compliance (NOC) to the latter for NeuraCeq (florbetaben F-18 injection). Isologic has received marketing authorization from Health Canada for the commercial production and market supply of NeuraCeq in Canada.

NeuraCeq is the first diagnostic radiotracer to support the early diagnosis of Alzheimer's disease (AD) that is commercially available in the country. NeuraCeq availability in Canada was previously limited to investigational medicine purposes.

"The commercial availability of NeuraCeq will provide physicians throughout Canada a non-invasive method to more confidently and accurately assess complex and atypical cases of cognitively impaired patients for early diagnosis of Alzheimer's disease," said Jean-Paul Soucy, M.D., medical director of PET (positron emission tomography) imaging at the Montreal Neurological Institute. "In the absence of an approved disease modifying treatment, advancing our ability to make an early and accurate AD diagnosis is critically important to providing optimal symptomatic treatment and non-pharmacological measures to manage disease progression and quality of life in these patients."

NeuraCeq has previously received approval from the U.S. Food and Drug Administration (FDA) and several countries in the European Union (EU) and Asia. It is a diagnostic radiotracer that when used in combination with PET imaging, can identify beta-amyloid plaques in the human brain, which are known as an important biomarker for Alzheimer's disease.

For more information: www.piramal.com/imaging

Related Content

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nucle

Tau (blue) and amyloid (orange) distribution patterns for super-agers, normal-agers and MCI patients, when compared to a group of younger, healthy, cognitively normal, amyloid-negative individuals. Brain projections are depicted at an uncorrected significance level of p < .0001. Color bars represent the respective t-statistic. Image courtesy of Merle C. Hoenig, Institute for Neuroscience and Medicine II - Molecular Organization of the Brain, Research Center Juelich, Juelich, Germany, and Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.

News | PET Imaging | July 16, 2020
July 16, 2020 — Super-agers, or individuals whose cognitive skills are above the norm even at an advanced age, have b
PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

PSMA PET/CT accurately detects recurrent prostate cancer in 67-year-old man. 18F-DCFPyL-PSMA PET/CT shows extensive, intensely PSMA-avid local recurrence in prostate (bottom row; solid arrow) in keeping with the known tumor recurrence in the prostate. Right: PET shows extensive, intensely PSMA-avid local recurrence in prostate (top row; solid arrow) and a solitary bone metastasis in left rib 2 (bottom row; dotted arrow). Image courtesy of Ur Metser, et al.

News | PET-CT | July 16, 2020
July 16, 2020 — New research confirms the high impact of...
Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs

Total-body dynamic 18F-FDG PET imaging with the uEXPLORER scanner allows us to monitor the spatiotemporal distribution of glucose concentration in metastatic tumors in the entire body (a). As compared to a typical clinical standardized uptake value image (b), the parametric image of FDG influx rate (Ki) can achieve higher lesion-to-background (e.g., the liver) contrast. In addition to glucose metabolism imaging by Ki, total-body dynamic PET also enables multiparametric characterization of tumors and organs using additional physiologically important parameters, for example, glucose transport rate K1 (d), across the entire body. Image courtesy of G.B. Wang, M. Parikh, L. Nardo, et al., University of California Davis, Calif.

News | PET Imaging | July 16, 2020
July 16, 2020 — Results from the first...
PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

PET/CT imaging showing uptake and retention of 86Y-NM600 (imaging agent) in immunocompetent mice bearing prostate tumors. PET imaging data was employed to estimate tumor dosimetry and prescribe an immunomodulatory 90Y-NM600 (therapy agent) injected activity. Image courtesy of R Hernandez et al., University of Wisconsin-Madison, WI.

News | PET-CT | July 15, 2020
July 15, 2020 — ...
Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

Representative maximum-intensity projection PET images of a healthy human volunteer injected with 64Cu-NOTA-EB-RGD at 1, 8, and 24 hours after injection. Axial MRI and PET slices of glioblastoma patient injected with 64Cu-NOTA-EB-RGD at different time points after injection. Image courtesy of Jingjing Zhang et al., Peking Union Medical College Hospital, Beijing, China/ Xiaoyuan Chen et al., Laboratory of Molecular Imaging and Nanomedicine, NIBIB/NIH, Bethesda, USA

News | PET Imaging | July 15, 2020
July 15, 2020 — A first-in-human study presented at the Society of...
Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the cont

Adult male with decades of right neck pain, discomfort and tightening following birth injury. The patient had failed multiple standard therapeutic maneuvers before presenting for 18F-FDG PET/MR imaging. Images shows abnormally elevated FDG uptake (white arrows; SUVmax = 1.2) observed in a linear pattern in the space in the posterolateral right neck, between the oblique capitis inferior and the semispinalis capitis muscles, where the greater occipital nerve resides. By comparison, the same region on the contralateral, asymptomatic side of the neck has an SUVmax = 0.7. This result encouraged a surgeon to explore the area. The surgeon ultimately found a collection of small arteries wrapped around the nerve in this location. The small arteries underwent lysis by the surgeon and the patient reported tremendous relief of symptoms. (A) Coronal thick slab MIP of 18F-FDG PET. (B) Axial LAVA FLEX MRI through the cervical spine. (C) Axial PET at the same slice as the axial MRI. (D) Fused axial PET/MRI. Image courtesy of Cipriano, et al., Stanford University, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — A new molecular imaging approach utilizing 18F-FDG...
Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total

Left: Total-body PET/CT in psoriatic arthritis: multiple joints affected, shoulders, elbows, wrists, knees, ankles and small joints of the hands/feet. Arrow: left wrist; arrowhead: right wrist. Middle: Total-body PET/CT in rheumatoid arthritis: multiple joints affected, right shoulder, small joints of the left hand. Arrowhead at the 4th proximal interphalangeal joint shows classic ring-like uptake pattern. Arrow on the foot images demonstrates the hammer toe deformity besides big toe arthritis. Right: Total-body PET/CT in osteoarthritis: affected joints include the left elbow, right knee (arrow) and right big toe (arrowhead). Image courtesy of YG Abdelhafez et al., University of California Davis, Sacramento, CA.

News | SNMMI | July 14, 2020
July 14, 2020 — For the first time, physicians can examine the systemic burden of inflammatory arthritis simultaneous